MULTIPLE MYELOMA

The FDA approves new denosumab biosimilars, expanding treatment options for osteoporosis and cancer-related bone issues, enhancing patient access to care.

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

The FDA clears the EXENT System, enhancing multiple myeloma diagnosis with automated workflows and improved sensitivity for clinical laboratories.

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

The FDA has approved daratumumab and hyaluronidase for the treatment of patients with high-risk smoldering multiple myeloma.

Talquetamab and daratumumab show high efficacy in treating relapsed/refractory multiple myeloma, with promising response rates and manageable safety profiles.

FDA approves new combinations for multiple myeloma treatment, enhancing survival rates and addressing unmet needs in patient care.

The FDA fast-tracks pamlectabart tismanitin, a promising treatment for relapsed multiple myeloma, enhancing its development and review process.

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

Cevostamab delivered feasible and well-tolerated antitumor activities post CAR T-cell therapy in patients with heavily pretreated multiple myeloma.

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.

A study reveals significant disparities in access to CAR T therapy for multiple myeloma among racial and ethnic minorities, despite similar treatment outcomes.

During a live event, Adriana Rossi, MD, discussed how cilta-cel induces responses and overcomes high-risk genetics in relapsed multiple myeloma.

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma patients, regardless of frailty changes.

Iberdomide combined with daratumumab and dexamethasone shows promising results in improving MRD negativity rates for relapsed multiple myeloma patients.

A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.

Experts explore the evolving treatment strategies for high-risk smoldering multiple myeloma, highlighting studies that show early intervention can improve patient outcomes.

Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma.

Binod Dhakal, MD, discusses the BOSTON trial of selinexor combination therapy in patients with relapsed/refractory multiple myeloma.

Recent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.

A novel trispecific antibody, JNJ-5322, shows remarkable efficacy in treating multiple myeloma, achieving a 100% response rate in trials.